Ibogaine neurotoxicity: a re-evaluation
Ibogaine is claimed to be an effective treatment for opiate and stimulant addiction. O'Hearn and Molliver, however, showed that ibogaine causes degeneration of cerebellar Purkinje cells in rats. The present study re-examined cerebellar responses to the high doses of ibogaine used by O'Hear...
Gespeichert in:
Veröffentlicht in: | Brain research 1996-10, Vol.737 (1), p.255-262 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 262 |
---|---|
container_issue | 1 |
container_start_page | 255 |
container_title | Brain research |
container_volume | 737 |
creator | Molinari, H.H Maisonneuve, I.M Glick, S.D |
description | Ibogaine is claimed to be an effective treatment for opiate and stimulant addiction. O'Hearn and Molliver, however, showed that ibogaine causes degeneration of cerebellar Purkinje cells in rats. The present study re-examined cerebellar responses to the high doses of ibogaine used by O'Hearn and Molliver (100 mg/kg or 3 × 100 mg/kg) and sought to determine whether a lower dose (40 mg/kg), one effective in reducing morphine and cocaine self-administration, produced similar responses. Purkinje cell degeneration was evaluated with a Fink-Heimer II stain, and enhanced glial cell activity with an antibody to glial fibrillary acidic protein. Every rat treated with the high dose of ibogaine displayed clear evidence of Purkinje cell degeneration. The degeneration consistently occurred in the intermediate and lateral cerebellum, as well as the vermis. Purkinje cells in lobules 5 and 6 were particularly susceptible. Given the response properties of cells in these lobules, this finding suggests any long-term motor deficits produced by ibogaine-induced degeneration should preferentially affect the head and upper extremity. In marked contrast, rats given the smaller dose of ibogaine displayed no degeneration above the level seen in saline-treated animals. When combined with information on other compounds, these data suggest that the degenerative and ‘anti-addictive’ properties of ibogaine reflect different actions of the drug. |
doi_str_mv | 10.1016/0006-8993(96)00739-1 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15747544</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0006899396007391</els_id><sourcerecordid>15747544</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-872beb43f9de60e0f85eb133eeca011b4e168d45d7c2373b1f3e83cab3c7ad3c3</originalsourceid><addsrcrecordid>eNp9UMtKAzEUDaLUWv0Dha58LEaT3swjLgQpPgoFN7oOedyRyHSiyUyxf2-Gli5dXQ73PDiHkHNGbxllxR2ltMgqIeBaFDeUliAydkDGrCpnWTHj9JCM95RjchLjV4IAgo7IqBJAoYQxuVpo_6lci9MW--A7_-uM6zb3UzUNmOFaNb3qnG9PyVGtmohnuzshH89P7_PXbPn2spg_LjPDgXdZytaoOdTCYkGR1lWOmgEgGkUZ0xxZUVme29LMUr5mNWAFRmkwpbJgYEIut77fwf_0GDu5ctFg06gWfR8ly0te5pwnIt8STfAxBqzld3ArFTaSUTnsI4fycigvxQDSPpIl2cXOv9crtHvRbpD0f9j-MZVcOwwyGoetQesCmk5a7_4P-AOKc3Pa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15747544</pqid></control><display><type>article</type><title>Ibogaine neurotoxicity: a re-evaluation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Molinari, H.H ; Maisonneuve, I.M ; Glick, S.D</creator><creatorcontrib>Molinari, H.H ; Maisonneuve, I.M ; Glick, S.D</creatorcontrib><description>Ibogaine is claimed to be an effective treatment for opiate and stimulant addiction. O'Hearn and Molliver, however, showed that ibogaine causes degeneration of cerebellar Purkinje cells in rats. The present study re-examined cerebellar responses to the high doses of ibogaine used by O'Hearn and Molliver (100 mg/kg or 3 × 100 mg/kg) and sought to determine whether a lower dose (40 mg/kg), one effective in reducing morphine and cocaine self-administration, produced similar responses. Purkinje cell degeneration was evaluated with a Fink-Heimer II stain, and enhanced glial cell activity with an antibody to glial fibrillary acidic protein. Every rat treated with the high dose of ibogaine displayed clear evidence of Purkinje cell degeneration. The degeneration consistently occurred in the intermediate and lateral cerebellum, as well as the vermis. Purkinje cells in lobules 5 and 6 were particularly susceptible. Given the response properties of cells in these lobules, this finding suggests any long-term motor deficits produced by ibogaine-induced degeneration should preferentially affect the head and upper extremity. In marked contrast, rats given the smaller dose of ibogaine displayed no degeneration above the level seen in saline-treated animals. When combined with information on other compounds, these data suggest that the degenerative and ‘anti-addictive’ properties of ibogaine reflect different actions of the drug.</description><identifier>ISSN: 0006-8993</identifier><identifier>EISSN: 1872-6240</identifier><identifier>DOI: 10.1016/0006-8993(96)00739-1</identifier><identifier>PMID: 8930373</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antibody Specificity ; Cerebellum ; Cerebellum - cytology ; Cerebellum - drug effects ; Dose-Response Relationship, Drug ; Evaluation Studies as Topic ; Female ; Fink-Heimer stain ; Glial fibrillary acidic protein ; Glial Fibrillary Acidic Protein - analysis ; Hallucinogens - toxicity ; Ibogaine ; Ibogaine - toxicity ; Nerve Degeneration - drug effects ; Nerve Tissue Proteins - analysis ; Nerve Tissue Proteins - immunology ; Neuroglia - chemistry ; Neuroglia - drug effects ; Neurotoxicity ; Neurotoxins - pharmacology ; Purkinje cell ; Purkinje Cells - drug effects ; Rats ; Rats, Sprague-Dawley ; Silver Staining ; Zebrin</subject><ispartof>Brain research, 1996-10, Vol.737 (1), p.255-262</ispartof><rights>1996 Elsevier Science B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-872beb43f9de60e0f85eb133eeca011b4e168d45d7c2373b1f3e83cab3c7ad3c3</citedby><cites>FETCH-LOGICAL-c434t-872beb43f9de60e0f85eb133eeca011b4e168d45d7c2373b1f3e83cab3c7ad3c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0006899396007391$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8930373$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Molinari, H.H</creatorcontrib><creatorcontrib>Maisonneuve, I.M</creatorcontrib><creatorcontrib>Glick, S.D</creatorcontrib><title>Ibogaine neurotoxicity: a re-evaluation</title><title>Brain research</title><addtitle>Brain Res</addtitle><description>Ibogaine is claimed to be an effective treatment for opiate and stimulant addiction. O'Hearn and Molliver, however, showed that ibogaine causes degeneration of cerebellar Purkinje cells in rats. The present study re-examined cerebellar responses to the high doses of ibogaine used by O'Hearn and Molliver (100 mg/kg or 3 × 100 mg/kg) and sought to determine whether a lower dose (40 mg/kg), one effective in reducing morphine and cocaine self-administration, produced similar responses. Purkinje cell degeneration was evaluated with a Fink-Heimer II stain, and enhanced glial cell activity with an antibody to glial fibrillary acidic protein. Every rat treated with the high dose of ibogaine displayed clear evidence of Purkinje cell degeneration. The degeneration consistently occurred in the intermediate and lateral cerebellum, as well as the vermis. Purkinje cells in lobules 5 and 6 were particularly susceptible. Given the response properties of cells in these lobules, this finding suggests any long-term motor deficits produced by ibogaine-induced degeneration should preferentially affect the head and upper extremity. In marked contrast, rats given the smaller dose of ibogaine displayed no degeneration above the level seen in saline-treated animals. When combined with information on other compounds, these data suggest that the degenerative and ‘anti-addictive’ properties of ibogaine reflect different actions of the drug.</description><subject>Animals</subject><subject>Antibody Specificity</subject><subject>Cerebellum</subject><subject>Cerebellum - cytology</subject><subject>Cerebellum - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Evaluation Studies as Topic</subject><subject>Female</subject><subject>Fink-Heimer stain</subject><subject>Glial fibrillary acidic protein</subject><subject>Glial Fibrillary Acidic Protein - analysis</subject><subject>Hallucinogens - toxicity</subject><subject>Ibogaine</subject><subject>Ibogaine - toxicity</subject><subject>Nerve Degeneration - drug effects</subject><subject>Nerve Tissue Proteins - analysis</subject><subject>Nerve Tissue Proteins - immunology</subject><subject>Neuroglia - chemistry</subject><subject>Neuroglia - drug effects</subject><subject>Neurotoxicity</subject><subject>Neurotoxins - pharmacology</subject><subject>Purkinje cell</subject><subject>Purkinje Cells - drug effects</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Silver Staining</subject><subject>Zebrin</subject><issn>0006-8993</issn><issn>1872-6240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UMtKAzEUDaLUWv0Dha58LEaT3swjLgQpPgoFN7oOedyRyHSiyUyxf2-Gli5dXQ73PDiHkHNGbxllxR2ltMgqIeBaFDeUliAydkDGrCpnWTHj9JCM95RjchLjV4IAgo7IqBJAoYQxuVpo_6lci9MW--A7_-uM6zb3UzUNmOFaNb3qnG9PyVGtmohnuzshH89P7_PXbPn2spg_LjPDgXdZytaoOdTCYkGR1lWOmgEgGkUZ0xxZUVme29LMUr5mNWAFRmkwpbJgYEIut77fwf_0GDu5ctFg06gWfR8ly0te5pwnIt8STfAxBqzld3ArFTaSUTnsI4fycigvxQDSPpIl2cXOv9crtHvRbpD0f9j-MZVcOwwyGoetQesCmk5a7_4P-AOKc3Pa</recordid><startdate>19961021</startdate><enddate>19961021</enddate><creator>Molinari, H.H</creator><creator>Maisonneuve, I.M</creator><creator>Glick, S.D</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>19961021</creationdate><title>Ibogaine neurotoxicity: a re-evaluation</title><author>Molinari, H.H ; Maisonneuve, I.M ; Glick, S.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-872beb43f9de60e0f85eb133eeca011b4e168d45d7c2373b1f3e83cab3c7ad3c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Animals</topic><topic>Antibody Specificity</topic><topic>Cerebellum</topic><topic>Cerebellum - cytology</topic><topic>Cerebellum - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Evaluation Studies as Topic</topic><topic>Female</topic><topic>Fink-Heimer stain</topic><topic>Glial fibrillary acidic protein</topic><topic>Glial Fibrillary Acidic Protein - analysis</topic><topic>Hallucinogens - toxicity</topic><topic>Ibogaine</topic><topic>Ibogaine - toxicity</topic><topic>Nerve Degeneration - drug effects</topic><topic>Nerve Tissue Proteins - analysis</topic><topic>Nerve Tissue Proteins - immunology</topic><topic>Neuroglia - chemistry</topic><topic>Neuroglia - drug effects</topic><topic>Neurotoxicity</topic><topic>Neurotoxins - pharmacology</topic><topic>Purkinje cell</topic><topic>Purkinje Cells - drug effects</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Silver Staining</topic><topic>Zebrin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Molinari, H.H</creatorcontrib><creatorcontrib>Maisonneuve, I.M</creatorcontrib><creatorcontrib>Glick, S.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Molinari, H.H</au><au>Maisonneuve, I.M</au><au>Glick, S.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ibogaine neurotoxicity: a re-evaluation</atitle><jtitle>Brain research</jtitle><addtitle>Brain Res</addtitle><date>1996-10-21</date><risdate>1996</risdate><volume>737</volume><issue>1</issue><spage>255</spage><epage>262</epage><pages>255-262</pages><issn>0006-8993</issn><eissn>1872-6240</eissn><abstract>Ibogaine is claimed to be an effective treatment for opiate and stimulant addiction. O'Hearn and Molliver, however, showed that ibogaine causes degeneration of cerebellar Purkinje cells in rats. The present study re-examined cerebellar responses to the high doses of ibogaine used by O'Hearn and Molliver (100 mg/kg or 3 × 100 mg/kg) and sought to determine whether a lower dose (40 mg/kg), one effective in reducing morphine and cocaine self-administration, produced similar responses. Purkinje cell degeneration was evaluated with a Fink-Heimer II stain, and enhanced glial cell activity with an antibody to glial fibrillary acidic protein. Every rat treated with the high dose of ibogaine displayed clear evidence of Purkinje cell degeneration. The degeneration consistently occurred in the intermediate and lateral cerebellum, as well as the vermis. Purkinje cells in lobules 5 and 6 were particularly susceptible. Given the response properties of cells in these lobules, this finding suggests any long-term motor deficits produced by ibogaine-induced degeneration should preferentially affect the head and upper extremity. In marked contrast, rats given the smaller dose of ibogaine displayed no degeneration above the level seen in saline-treated animals. When combined with information on other compounds, these data suggest that the degenerative and ‘anti-addictive’ properties of ibogaine reflect different actions of the drug.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>8930373</pmid><doi>10.1016/0006-8993(96)00739-1</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-8993 |
ispartof | Brain research, 1996-10, Vol.737 (1), p.255-262 |
issn | 0006-8993 1872-6240 |
language | eng |
recordid | cdi_proquest_miscellaneous_15747544 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Animals Antibody Specificity Cerebellum Cerebellum - cytology Cerebellum - drug effects Dose-Response Relationship, Drug Evaluation Studies as Topic Female Fink-Heimer stain Glial fibrillary acidic protein Glial Fibrillary Acidic Protein - analysis Hallucinogens - toxicity Ibogaine Ibogaine - toxicity Nerve Degeneration - drug effects Nerve Tissue Proteins - analysis Nerve Tissue Proteins - immunology Neuroglia - chemistry Neuroglia - drug effects Neurotoxicity Neurotoxins - pharmacology Purkinje cell Purkinje Cells - drug effects Rats Rats, Sprague-Dawley Silver Staining Zebrin |
title | Ibogaine neurotoxicity: a re-evaluation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T21%3A13%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ibogaine%20neurotoxicity:%20a%20re-evaluation&rft.jtitle=Brain%20research&rft.au=Molinari,%20H.H&rft.date=1996-10-21&rft.volume=737&rft.issue=1&rft.spage=255&rft.epage=262&rft.pages=255-262&rft.issn=0006-8993&rft.eissn=1872-6240&rft_id=info:doi/10.1016/0006-8993(96)00739-1&rft_dat=%3Cproquest_cross%3E15747544%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15747544&rft_id=info:pmid/8930373&rft_els_id=0006899396007391&rfr_iscdi=true |